Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

NCT07509112 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT07509112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07509112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Lead sponsor
Kirby Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2027
Enrollment
40 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine use disorder